RESUMO
Objective To examine treatment utilization patterns and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in routine clinical practice. Background Clinical trials support onabotulinumtoxinA for the prophylaxis of headache in patients with chronic migraine, but real-world data are limited. Design/methods A prospective, observational, post-authorization study in adult patients with chronic migraine treated with onabotulinumtoxinA. Data were collected at the first study injection and approximately every three months for ≤52 weeks for utilization and ≤64 weeks for safety data, and summarized using descriptive statistics. Results Eighty-five physicians (81% neurologists) at 58 practices in the United Kingdom, Germany, Spain, and Sweden participated and recruited 1160 patients (84.2% female, median age 46.6 years). At baseline, 85.8% of patients had physician diagnoses of chronic migraine/transformed migraine and reported an average of 11.3 (SD = 6.9) severe headache days per 28 days; 50.6% had previously used onabotulinumtoxinA for chronic migraine. A total of 4017 study treatments were observed. The median number of injection sites (n = 31) and total dose (155 U) were consistent across all treatment sessions, with a median 13.7 weeks observed between sessions. At least one treatment-related adverse event was reported by 291 patients (25.1%); the most frequently reported treatment-related adverse event was neck pain (4.4%). Most patients (74.4%) were satisfied/extremely satisfied with onabotulinumtoxinA treatment. Conclusions Patient demographics/characteristics are consistent with published data on the chronic migraine population. Utilization of onabotulinumtoxinA treatment for chronic migraine appears to be consistent with the Summary of Product Characteristics and published PREEMPT injection paradigm. No new safety signals were identified.
Assuntos
Inibidores da Liberação da Acetilcolina/administração & dosagem , Toxinas Botulínicas Tipo A/administração & dosagem , Internacionalidade , Transtornos de Enxaqueca/epidemiologia , Transtornos de Enxaqueca/prevenção & controle , Profilaxia Pré-Exposição/métodos , Inibidores da Liberação da Acetilcolina/efeitos adversos , Adulto , Blefaroptose/induzido quimicamente , Toxinas Botulínicas Tipo A/efeitos adversos , Doença Crônica , Europa (Continente)/epidemiologia , Feminino , Humanos , Injeções Intramusculares , Masculino , Pessoa de Meia-Idade , Transtornos de Enxaqueca/diagnóstico , Cervicalgia/induzido quimicamente , Estudos Prospectivos , Resultado do TratamentoRESUMO
Endothelin-1 (ET-1) is a newly described pain mediator that is involved in the pathogenesis of pain states ranging from trauma to cancer. ET-1 is synthesized by keratinocytes in normal skin and is locally released after cutaneous injury. While it is able to trigger pain through its actions on endothelin-A (ET(A)) receptors of local nociceptors, it can coincidentally produce analgesia through endothelin-B (ET(B)) receptors. Here we map a new endogenous analgesic circuit, in which ET(B) receptor activation induces the release of beta-endorphin from keratinocytes and the activation of G-protein-coupled inwardly rectifying potassium channels (GIRKs, also named Kir-3) linked to opioid receptors on nociceptors. These results indicate the existence of an intrinsic feedback mechanism to control peripheral pain in skin, and establish keratinocytes as an ET(B) receptor-operated opioid pool.
Assuntos
Analgesia , Dor/metabolismo , Canais de Potássio Corretores do Fluxo de Internalização , Receptores de Endotelina/metabolismo , Transdução de Sinais , Pele/lesões , Animais , Células Cultivadas , Endotelina-1/metabolismo , Canais de Potássio Corretores do Fluxo de Internalização Acoplados a Proteínas G , Humanos , Queratinócitos/citologia , Queratinócitos/metabolismo , Masculino , Medição da Dor , Canais de Potássio/metabolismo , Ratos , Ratos Sprague-Dawley , Receptor de Endotelina B , Receptores Opioides delta/metabolismo , Receptores Opioides kappa/metabolismo , Receptores Opioides mu/metabolismo , Pele/citologia , beta-Endorfina/metabolismoRESUMO
Complex regional pain syndromes (CRPS, type I and type II) are devastating conditions that can occur following soft tissue (CRPS type I) or nerve (CRPS type II) injury. CRPS type I, also known as reflex sympathetic dystrophy, presents in patients lacking a well-defined nerve lesion, and has been questioned as to whether or not it is a true neuropathic condition with an organic basis. As described here, glabrous and hairy skin samples from the amputated upper and lower extremity from two CRPS type I diagnosed patients were processed for double-label immunofluorescence using a battery of antibodies directed against neural-related proteins and mediators of nociceptive sensory function. In CRPS affected skin, several neuropathologic alterations were detected, including: (1) the presence of numerous abnormal thin caliber NF-positive/MBP-negative axons innervating hair follicles; (2) a decrease in epidermal, sweat gland, and vascular innervation; (3) a loss of CGRP expression on remaining innervation to vasculature and sweat glands; (4) an inappropriate expression of NPY on innervation to superficial arterioles and sweat glands; and (5) a loss of vascular endothelial integrity and extraordinary vascular hypertrophy. The results are evidence of widespread cutaneous neuropathologic changes. Importantly, in these CRPS type I patients, the myriad of clinical symptoms observed had detectable neuropathologic correlates.
Assuntos
Vias Aferentes/patologia , Fibras Nervosas/patologia , Doenças do Sistema Nervoso Periférico/patologia , Doenças Vasculares Periféricas/patologia , Distrofia Simpática Reflexa/patologia , Pele/irrigação sanguínea , Pele/inervação , Adulto , Axônios/patologia , Medicina Baseada em Evidências , Extremidades/irrigação sanguínea , Extremidades/inervação , Extremidades/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Pele/patologiaRESUMO
Endothelin-1 (ET-1) causes pain through activation of nociceptors, by either direct depolarization or increased excitability. Here we examined the effect of ET-1 on nociceptor-associated tetrodotoxin-resistant (TTX-R) sodium currents using whole-cell voltage clamp of acutely dissociated rat dorsal root ganglion (DRG) neurons. DRG neurons that responded had enhanced activation gating when exposed to 10 nm ET-1, as determined by significant shifts in their average activation midpoint potentials (DeltaE(0.5) = -8.0 +/- 0.5 mV) when compared with control (DeltaE(0.5) = -2.2 +/- 0.4 mV; n = 6) and ET-1 unresponsive cells (DeltaE(0.5) = -3.2 +/- 0.2 mV). ET-1 also modified the availability of TTX-R channels, as determined by negative shifts in the average midpoint potential for inactivation of ET-1 responsive cells when compared with controls. These actions of ET-1 occurred predominantly in cells with more slowly inactivating TTX-R currents. Both time-to-peak current and inactivation time constants were shortened by ET-1 in responsive cells. Previous exposure of cells to the endothelin-A (ET(A)) receptor antagonist BQ-123 (1 microm) prevented ET-1-induced shifts in TTX-R activation. In contrast to changes in TTX-R, ET-1 did not modify tetrodotoxin-sensitive currents recorded from DRG neurons. These results demonstrate that the algogenic peptide ET-1 induces ET(A) receptor-mediated, hyperpolarizing shifts in the voltage-dependent activation of TTX-R Na+ channels, a potential mechanism for selective excitation by ET-1 of nociceptors that we observed in vivo.
Assuntos
Endotelina-1/farmacologia , Ativação do Canal Iônico/efeitos dos fármacos , Neurônios Aferentes/metabolismo , Nociceptores/metabolismo , Dor/metabolismo , Canais de Sódio/metabolismo , Animais , Separação Celular , Células Cultivadas , Gânglios Espinais/citologia , Gânglios Espinais/metabolismo , Ativação do Canal Iônico/fisiologia , Cinética , Masculino , Potenciais da Membrana/efeitos dos fármacos , Potenciais da Membrana/fisiologia , Neurônios Aferentes/citologia , Nociceptores/efeitos dos fármacos , Dor/induzido quimicamente , Técnicas de Patch-Clamp , Ratos , Ratos Sprague-Dawley , Receptor de Endotelina A , Receptores de Endotelina/metabolismo , Sódio/metabolismo , Canais de Sódio/efeitos dos fármacos , Tetrodotoxina/farmacologiaRESUMO
We showed previously that subcutaneous injection of the injury-associated peptide mediator endothelin-1 (ET-1) into the rat plantar hindpaw produces pain behavior and selective excitation of nociceptors, both through activation of ET(A) receptors likely on nociceptive terminals. The potential role of ET(B) receptor activation in these actions of ET-1-has not been examined. Therefore, in these experiments, we studied the effect of blocking or activating ET(B) receptors on ET-1-induced hindpaw flinching and excitation of nociceptors in rats. An ET(B) receptor-selective antagonist, BQ-788 (3 mm), coinjected with ET-1 (200 microm) reduced the time-to-peak of flinching and significantly enhanced the average maximal flinch frequency (MFF). In contrast, coinjection of an ET(B) receptor selective agonist, IRL-1620 (100 or 200 microm), with ET-1 reduced the average MFF and the average total number of flinches. Interestingly, this unexpected inhibitory effect of IRL-1620 was prevented by the nonselective opioid receptor antagonist naloxone (2.75 mm). To confirm these inhibitory actions, we studied the effects of IRL-1620 on ET-1-induced spike responses in single, physiologically characterized nociceptive C-fibers. IRL-1620 suppressed spike responses to ET-1 in all (n = 12) C-units, with mean and maximum response frequencies of 0.08 +/- 0.02 and 1.5 +/- 0.4 impulses/sec versus 0.32 +/- 0.07 and 4.17 +/- 0.17 impulses/sec for ET-1 alone. In additional support of the behavioral results, coinjection of naloxone (2.75 mm) completely prevented this inhibitory action of IRL-1620. These results establish that ET(B) receptor activation inhibits ET-1-induced pain behavior and nociception in a naloxone-sensitive manner and point to a previously unrecognized dual modulation of acute nociceptive signaling by ET(A) and ET(B) receptors in cutaneous tissues.
Assuntos
Endotelina-1/farmacologia , Naloxona/farmacologia , Nociceptores/efeitos dos fármacos , Dor/tratamento farmacológico , Receptores de Endotelina/agonistas , Potenciais de Ação/efeitos dos fármacos , Potenciais de Ação/fisiologia , Animais , Comportamento Animal/efeitos dos fármacos , Relação Dose-Resposta a Droga , Antagonismo de Drogas , Sinergismo Farmacológico , Antagonistas dos Receptores de Endotelina , Endotelinas/farmacologia , Membro Posterior/efeitos dos fármacos , Membro Posterior/inervação , Membro Posterior/fisiopatologia , Injeções Subcutâneas , Masculino , Fibras Nervosas/efeitos dos fármacos , Fibras Nervosas/fisiologia , Nociceptores/fisiopatologia , Oligopeptídeos/farmacologia , Dor/induzido quimicamente , Dor/fisiopatologia , Medição da Dor/efeitos dos fármacos , Fragmentos de Peptídeos/farmacologia , Piperidinas/farmacologia , Ratos , Ratos Sprague-Dawley , Tempo de Reação/efeitos dos fármacos , Receptor de Endotelina BRESUMO
Comprised mainly of depression, anxiety, and high neuroticism, psychopathology diminishes the effectiveness of many chronic pain treatments. But, it is not known if it is associated with diminished opioid analgesia in patients with chronic, noncancer pain. We tested the hypothesis that psychopathology diminishes opioid analgesia in patients with discogenic low back pain in 60 patients not on opioids in a double blind, placebo controlled, random crossover designed trial. Patients were stratified into three groups of psychological symptom severity (LOW, MOD, and HIGH), based on composite scores on depression, anxiety for pain, and neuroticism scales. Subjects were given intravenous morphine (4-6mg dosed by ideal body weight) and placebo in random order on separate visits, and completed serial pain ratings over three hours at each session. With 20 subjects per group, there were nonsignificant differences between groups in the distribution of age, gender, baseline pain (avg. 6.1/10), radicular pain, and morphine dose (5.0mg). For morphine analgesia, using a total pain relief calculation (TOTPAR), the LOW group had 65.1% TOTPAR vs. 41.0% in the HIGH group, P=.026. For placebo analgesia the LOW group had 7.7% TOTPAR vs. 23.5% in the HIGH group, P=.03. A morphine minus placebo analgesia calculation revealed 59.2% TOTPAR in the LOW group vs. 21.7% in the HIGH group, P=.0001. High levels of psychopathology are associated with diminished opioid analgesia in patients with discogenic low back pain. These results have implications for the prescription of oral opioids to patients with chronic low back pain and psychopathology.
Assuntos
Analgésicos Opioides/administração & dosagem , Sintomas Comportamentais/tratamento farmacológico , Dor Lombar/tratamento farmacológico , Morfina/administração & dosagem , Adulto , Idoso , Análise de Variância , Sintomas Comportamentais/etiologia , Estudos de Casos e Controles , Estudos Cross-Over , Demografia , Avaliação da Deficiência , Método Duplo-Cego , Feminino , Humanos , Injeções Intravenosas/métodos , Modelos Lineares , Dor Lombar/classificação , Dor Lombar/complicações , Masculino , Pessoa de Meia-Idade , Modelos Psicológicos , Medição da Dor , Limiar da Dor/efeitos dos fármacos , Inventário de Personalidade/estatística & dados numéricos , Efeito Placebo , Testes Psicológicos , Perfil de Impacto da Doença , Resultado do TratamentoRESUMO
Hereditary sensory neuropathy Type II (HSN II) is an autosomal recessive disorder characterized by the loss of peripheral sensory modalities in individuals with otherwise normal development. Patients with HSN II often have chronic ulceration of the fingers and toes, autoamputation of the distal phalanges, and neuropathic joint degeneration associated with loss of pain sensation. Recent descriptions of a similar phenotype in mice carrying a targeted mutation in the low affinity nerve growth factor receptor, p75NGFR, suggested the possibility that mutations in this gene or other members of the nerve growth factor (NGF) family of genes and their receptors might be responsible for this human disorder. In this study candidate genes were evaluated by their inheritance pattern in two sisters affected with HSN II, their unaffected sister and mother in a consanguineous family. The segregation of polymorphic alleles at and around loci for p75NGFR, TRKA, TRKB, BDNF, and familial dysautonomia (another hereditary sensory neuropathy having features in common with HSN II) virtually excluded these genes as the cause of HSN II in this family. Further evaluation of loci for other neurotrophic factors and their receptors, which will be possible when mapping information on their loci becomes available, may permit the identification of the gene responsible for HSN II.
Assuntos
Genes , Neuropatias Hereditárias Sensoriais e Autônomas/genética , Receptores de Fator de Crescimento Neural/genética , Doenças do Sistema Nervoso Autônomo/genética , Fator Neurotrófico Derivado do Encéfalo/genética , Mapeamento Cromossômico , Feminino , Humanos , Linhagem , Reação em Cadeia da Polimerase , Polimorfismo Genético , Receptor do Fator Neutrófico Ciliar , Receptor de Fator de Crescimento Neural , Receptor trkA/genéticaRESUMO
Endothelin-1 (ET-1) applied to the sciatic nerve or injected into the plantar hindpaw of rats induces pain behavior (ipsilateral hindpaw flinching) and selective excitation of nociceptors by activation of endothelin-A (ET(A)) receptors. To determine the pharmacological profile of the sensory fibers that mediate this pain behavior, we administered lidocaine (LID, a non-selective conduction blocker) or tetrodotoxin (TTX) prior to ET-1. LID (1 or 2%, 0.1 ml) was injected percutaneously into the sciatic notch, or TTX (10 microM, 4 microl) was injected into the sciatic nerve prior to the more distal application of ET-1 (400 microM, 40 microl) onto the sciatic nerve or subcutaneously into the plantar hindpaw (400 microM, 10 microl). LID inhibited ET-1-induced flinching in a dose-dependent manner; the mean total number of flinches was reduced by 39% for 1% LID and by 87% for 2% LID. In contrast, TTX failed to inhibit flinching behavior induced by sciatic nerve application of ET-1 despite a similar magnitude of motor and sensory blockade as that observed with 2% LID. Partial blockade of flinching behavior by intraneural TTX (mean total flinches were reduced by 51%) was observed after subcutaneous injection of ET-1. Unexpectedly, ET-1 prolonged the actions of 1% LID and, even when applied alone, produced clear signs of motor and sensory conduction block. These results are evidence that ET-1-induced pain is transmitted to the central nervous system via sensory fibers using tetrodotoxin-resistant sodium channels, and that ET-1 has analgesic actions that exist despite the activation of local pain pathways.
Assuntos
Endotelina-1/toxicidade , Neurônios Aferentes/efeitos dos fármacos , Medição da Dor/efeitos dos fármacos , Dor/induzido quimicamente , Tetrodotoxina/toxicidade , Animais , Relação Dose-Resposta a Droga , Masculino , Neurônios Aferentes/fisiologia , Dor/fisiopatologia , Medição da Dor/métodos , Ratos , Ratos Sprague-Dawley , Nervo Isquiático/efeitos dos fármacos , Nervo Isquiático/fisiologiaRESUMO
The clinical characteristics of complex regional pain syndrome (CRPS)--spontaneous and stimulus-evoked pain, autonomic abnormalities, motor dysfunction, and trophic changes in the affected limb--are well known. However, its pathogenesis is unclear, and the diagnosis is often delayed, in part due to lack of objective laboratory tests. Endothelin-1 (ET-1) is a potent vasoconstrictor that has recently been shown to produce pain, allodynia, edema, and muscle weakness, as well as to exert a direct excitatory effect on nociceptive afferents. Furthermore, new evidence indicates that ET-1 is involved in various cancer- and non-cancer-related painful conditions. The aim of the present explorative study was to determine the ET-1 plasma levels in patients with CRPS in an attempt to identify a 'laboratory marker' for CRPS and to search for evidence suggesting that ET-1 may be involved in the pathogenesis of CRPS. ET-1 plasma levels were determined in 20 severely affected CRPS patients, in eight patients with non-CRPS chronic painful conditions, and in 10 healthy volunteers. The results showed that there were no significant differences in ET-1 plasma levels between the three groups. We conclude that the plasma level of ET-1 cannot be regarded as a 'marker' for CRPS. Yet, the possibility that ET-1 is involved in the pathophysiology of CRPS has not been excluded and deserves further investigation.
Assuntos
Síndromes da Dor Regional Complexa/sangue , Endotelina-1/sangue , Adulto , Síndromes da Dor Regional Complexa/psicologia , Ensaio de Imunoadsorção Enzimática , Feminino , Lateralidade Funcional/fisiologia , Humanos , Masculino , Medição da Dor , Limiar da Dor , Inquéritos e QuestionáriosRESUMO
This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple sclerosis, in healthy volunteers. Two randomized, blinded phase I studies were conducted: a single-dose study (n = 60) comparing subcutaneous or intramuscular PEG-IFN beta-1a (63, 125, or 188 µg) with intramuscular unmodified IFN beta-1a 30 µg and a multiple-dose study (n = 69) comparing subcutaneous PEG-IFN beta-1a dosed once every 2 or 4 weeks with placebo. Assessments included pharmacokinetic and pharmacodynamic (serum neopterin and 2',5'-OAS) measures, exploratory immune assessments, safety, and tolerability. A dose-proportional increase in PEG-IFN beta-1a exposure was observed, with a 4-fold greater exposure at 63 µg (6 million international units [MIU]) of PEG-IFN beta-1a than with 30 µg (6 MIU) intramuscular unmodified IFN beta-1a. Increases in neopterin and 2',5'-OAS levels and changes in T helper cell pathway gene expression and lymphocyte subsets were greater and more sustained with PEG-IFN beta-1a than with unmodified IFN beta-1a. PEG-IFN beta-1a was well tolerated, with only transient reductions in absolute neutrophils and some lymphocytes. Flu-like symptoms were a commonly reported adverse event. These data support the continued clinical development of PEG-IFN beta-1a as a potentially effective treatment for patients with relapsing multiple sclerosis.
Assuntos
Imunossupressores/efeitos adversos , Interferon beta/química , Interferons/efeitos adversos , Polietilenoglicóis/efeitos adversos , 2',5'-Oligoadenilato Sintetase/sangue , 2',5'-Oligoadenilato Sintetase/genética , 2',5'-Oligoadenilato Sintetase/metabolismo , Adolescente , Adulto , Biotransformação , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Meia-Vida , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/sangue , Imunossupressores/farmacologia , Injeções Intramusculares , Injeções Subcutâneas , Interferon beta/administração & dosagem , Interferon beta/efeitos adversos , Interferon beta/farmacologia , Interferons/administração & dosagem , Interferons/sangue , Interferons/farmacologia , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Neopterina/sangue , Polietilenoglicóis/administração & dosagem , Polietilenoglicóis/farmacologia , RNA Mensageiro/sangue , RNA Mensageiro/metabolismo , Linfócitos T Auxiliares-Indutores/efeitos dos fármacos , Linfócitos T Auxiliares-Indutores/metabolismo , Adulto JovemRESUMO
Multiple sclerosis is a chronic autoimmune disease of the central nervous system for which a number of disease-modifying therapies are available, including interferon beta (Avonex®, Rebif®, and Betaseron/Betaferon®), glatiramer acetate (Copaxone®), and an anti-VLA4 monoclonal antibody (Tysabri®). Despite the availability and efficacy of these protein and peptide drugs, there remains a significant number of patients who are untreated, including those with relatively mild disease who choose not to initiate therapy, those wary of injections or potential adverse events associated with therapy, and those who have stopped therapy due to perceived lack of efficacy. Since these drugs have side effects that may affect a patient's decision to initiate and to remain on treatment, there is a need to provide a therapy that is safe and efficacious but that requires a reduced dosing frequency and hence a concomitant reduction in the frequency of side effects. Here we describe the development of a PEGylated form of interferon beta-1a that is currently being tested in a multicenter, randomized, double-blind, parallel-group, placebo-controlled study in relapsing multiple sclerosis patients, with the aim of determining the safety and efficacy of 125 microg administered via the subcutaneous route every 2 or 4 weeks.
Assuntos
Interferon beta/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Polietilenoglicóis/química , Humanos , Interferon beta-1a , Interferon beta/efeitos adversos , Interferon beta/imunologia , Esclerose Múltipla/imunologia , Polietilenoglicóis/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , RecidivaRESUMO
Injection of endothelin-1 (ET-1) into the plantar rat hindpaw causes acute pain at high concentrations and tactile sensitization at low concentrations. The pro-nociceptive actions are driven through ET(A) receptors for both levels of [ET-1], but the ET(B) receptors are only pro-nociceptive for allodynia from low [ET-1] and anti-nociceptive for pain from high [ET-1]. The goal of the present work was to discriminate the roles of the ET receptors in the acute hyperalgesia from inflammation by complete Freund's adjuvant (CFA, 20 mg/paw) into the rat hindpaw. Selective antagonists were injected l0 min before and then together with CFA. An ET(A) receptor antagonist, BQ-123, reduced CFA-induced thermal hyperalgesia (by up to 50%), as did an ET(B) receptor antagonist, BQ-788 (by up to 66%). BQ-123 and BQ-788 also delayed the onset (by 1.5 - 2 h) but insignificantly reduced the maximum degree of CFA-induced allodynia (~10%). Surprisingly, an ET(B) receptor agonist, IRL-1620, also reduced maximum thermal hyperalgesia induced by CFA, suppressed peak allodynia and delayed its occurrence by ~ 3 h. The latter actions of IRL-1620 were reversed by co-administration of BQ-788, naloxone hydrochloride and the peripherally restricted opiate receptor antagonist naloxone methiodide, and by antiserum against ß-endorphin. These findings demonstrate an important role for endogenous ET-1 in acute inflammatory pain and a dual action of ET(B) receptors, including a pro-algesic action along with the important activation of a local analgesic pathway, implying that at least two different ET(B) receptors contribute to modulation of inflammatory pain.
RESUMO
The vanilloid receptor TRPV1 has been identified as a molecular target for the treatment of pain associated with inflammatory diseases and cancer. Hence, TRPV1 antagonists have been considered for therapeutic evaluation in such diseases. During Phase I clinical trials with AMG 517, a highly selective TRPV1 antagonist, we found that TRPV1 blockade elicited marked, but reversible, and generally plasma concentration-dependent hyperthermia. Similar to what was observed in rats, dogs, and monkeys, hyperthermia was attenuated after repeated dosing of AMG 517 (at the highest dose tested) in humans during a second Phase I trial. However, AMG 517 administered after molar extraction (a surgical cause of acute pain) elicited long-lasting hyperthermia with maximal body temperature surpassing 40 degrees C, suggesting that TRPV1 blockade elicits undesirable hyperthermia in susceptible individuals. Mechanisms of AMG 517-induced hyperthermia were then studied in rats. AMG 517 caused hyperthermia by inducing tail skin vasoconstriction and increasing thermogenesis, which suggests that TRPV1 regulates vasomotor tone and metabolic heat production. In conclusion, these results demonstrate that: (a) TRPV1-selective antagonists like AMG 517 cannot be developed for systemic use as stand alone agents for treatment of pain and other diseases, (b) individual susceptibility influences magnitude of hyperthermia observed after TRPV1 blockade, and (c) TRPV1 plays a pivotal role as a molecular regulator for body temperature in humans.
Assuntos
Benzotiazóis/efeitos adversos , Febre/induzido quimicamente , Febre/fisiopatologia , Pirimidinas/efeitos adversos , Canais de Cátion TRPV/antagonistas & inibidores , Canais de Cátion TRPV/fisiologia , Adulto , Animais , Benzotiazóis/farmacologia , Estudos de Coortes , Relação Dose-Resposta a Droga , Método Duplo-Cego , Humanos , Masculino , Pirimidinas/farmacologia , Ratos , Ratos WistarRESUMO
BACKGROUND: Chronic low back pain patients have a high rate of psychopathology, comprised mainly of depression, anxiety, and high levels of neuroticism. We previously found that psychopathology is associated with increased placebo analgesia in this patient group. OBJECTIVE: To better understand this finding in the context of other known predictors of placebo response (such as expectations for relief), we performed a detailed analysis of expectations and other possible covariates. DESIGN: We conducted a double-blind, placebo-controlled, randomized, crossover-designed trial of intravenous morphine vs. placebo in 60 subjects with chronic low back pain and discogenic abnormalities. Patients were stratified into three groups of psychiatric symptom severity (Low, Moderate, and High), based on composite scores on depression, anxiety for pain, and neuroticism scales. Subjects were given intravenous morphine and placebo in random order on separate visits, and completed serial pain ratings over 3 h at each session. RESULTS: With 20 subjects per group, there were small, but significant differences between groups in baseline pain ratings. No differences were found between groups in age, gender, and radicular pain. Patients with low psychological symptomatology reported 7.7% total pain relief with placebo compared with 23.4% in the Moderate group and 23.5% in the High group (P < 0.05). Expectations were not significantly different between groups, but in the High group expectation levels predicted placebo analgesia (P < 0.001). Neuropathic pain quality was also a predictor (P < 0.05). CONCLUSIONS: This study indicates that high and moderate levels of psychopathology are associated with heightened placebo analgesia in chronic low back pain patients. Expectations were only an influence in the high psychopathology group, and neuropathic pain affects placebo responses. These findings have implications for future research characterizing placebo responders.
Assuntos
Ansiedade/epidemiologia , Sintomas Comportamentais/tratamento farmacológico , Deslocamento do Disco Intervertebral/epidemiologia , Dor Lombar/tratamento farmacológico , Dor Lombar/epidemiologia , Morfina/administração & dosagem , Medição de Risco/métodos , Adulto , Analgésicos Opioides/administração & dosagem , Ansiedade/tratamento farmacológico , Ansiedade/psicologia , Atitude Frente a Saúde , Sintomas Comportamentais/epidemiologia , Sintomas Comportamentais/psicologia , Comorbidade , Estudos Cross-Over , Método Duplo-Cego , Emprego/estatística & dados numéricos , Feminino , Humanos , Incidência , Injeções Intravenosas , Deslocamento do Disco Intervertebral/tratamento farmacológico , Deslocamento do Disco Intervertebral/psicologia , Dor Lombar/psicologia , Masculino , Efeito Placebo , Psicopatologia/métodos , Fatores de Risco , Estatística como Assunto , Estados UnidosRESUMO
CB(2) cannabinoid receptor-selective agonists are promising candidates for the treatment of pain. CB(2) receptor activation inhibits acute, inflammatory, and neuropathic pain responses but does not cause central nervous system (CNS) effects, consistent with the lack of CB(2) receptors in the normal CNS. To date, there has been virtually no information regarding the mechanism of CB(2) receptor-mediated inhibition of pain responses. Here, we test the hypothesis that CB(2) receptor activation stimulates release from keratinocytes of the endogenous opioid beta-endorphin, which then acts at opioid receptors on primary afferent neurons to inhibit nociception. The antinociceptive effects of the CB(2) receptor-selective agonist AM1241 were prevented in rats when naloxone or antiserum to beta-endorphin was injected in the hindpaw where the noxious thermal stimulus was applied, suggesting that beta-endorphin is necessary for CB(2) receptor-mediated antinociception. Further, AM1241 did not inhibit nociception in mu-opioid receptor-deficient mice. Hindpaw injection of beta-endorphin was sufficient to produce antinociception. AM1241 stimulated beta-endorphin release from rat skin tissue and from cultured human keratinocytes. This stimulation was prevented by AM630, a CB(2) cannabinoid receptor-selective antagonist and was not observed in skin from CB(2) cannabinoid receptor-deficient mice. These data suggest that CB(2) receptor activation stimulates release from keratinocytes of beta-endorphin, which acts at local neuronal mu-opioid receptors to inhibit nociception. Supporting this possibility, CB(2) immunolabeling was detected on beta-endorphin-containing keratinocytes in stratum granulosum throughout the epidermis of the hindpaw. This mechanism allows for the local release of beta-endorphin, where CB(2) receptors are present, leading to anatomical specificity of opioid effects.
Assuntos
Analgésicos/farmacologia , Receptor CB2 de Canabinoide/fisiologia , beta-Endorfina/metabolismo , Animais , Canabinoides , Células Cultivadas , Humanos , Masculino , Ratos , Ratos Sprague-Dawley , Receptor CB2 de Canabinoide/agonistas , Receptor de Endotelina B/fisiologiaRESUMO
Hereditary sensory and autonomic neuropathy (HSAN) type II is an autosomal recessive disorder characterized by impairment of pain, temperature, and touch sensation owing to reduction or absence of peripheral sensory neurons. We identified two large pedigrees segregating the disorder in an isolated population living in Newfoundland and performed a 5-cM genome scan. Linkage analysis identified a locus mapping to 12p13.33 with a maximum LOD score of 8.4. Haplotype sharing defined a candidate interval of 1.06 Mb containing all or part of seven annotated genes, sequencing of which failed to detect causative mutations. Comparative genomics revealed a conserved ORF corresponding to a novel gene in which we found three different truncating mutations among five families including patients from rural Quebec and Nova Scotia. This gene, termed "HSN2," consists of a single exon located within intron 8 of the PRKWNK1 gene and is transcribed from the same strand. The HSN2 protein may play a role in the development and/or maintenance of peripheral sensory neurons or their supporting Schwann cells.